Related Suggestion
Mucormycosis
or black fungus, a devastating infection that soars in India during COVID-19
has seized global attention. Recently, the country's mucormycosis cases reached
over 57,150 and resulted in 54% mortality. Apart
from the association with high diabetes prevalence in India, COVID-19 infected
countries (Pakistan, Russia, Nepal, Chile, Brazil, etc.) have
also described the same issue, areas with high diabetes and COVID-19 infection
rates should be alarmed.
Unfortunately, mucormycosis is always being diagnosed
late with prolonged COVID-19 healthcare burdens that deteriorate the situation. As a company making continuous research
and contribution to the world's major infectious diseases with the mission to Enable Disease Identification Earlier, More Accurate,
Convenient and Affordable, Fapon Biotech Inc. (Fapon Biotech) calls for cooperation with academic
and industry partners in developing mucormycosis diagnostic tests to ease
the challenge by sharing the abilities of upstream raw material development
platforms and downstream reagent application platforms.
Your Trusted Partners, Fapon Biotech Inc.
Accelerate Your Workflow of Black Fungus Assay
from Biomarker Discovery to Commercialization
As the virus continues its mutation and
triggers diseases like mucormycosis to complicate the situation, rapid
responses via global cooperation will be crucial for areas with overwhelmed
healthcare burdens. Fapon Biotech is committed to fueling the advancement of
COVID-19 diagnosis through collaborations with international IVD partners.